

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Axel ULLRICH et al.
Title: TREATMENT OF DIABETES MELLITUS AND
INSULIN RECEPTOR SIGNAL TRANSDUCTION
Prior Appl. No.: 09/232,073
Prior Appl. Filing Date: 01/15/1999
Examiner: P. Patten
Art Unit: 1651

CONTINUING PATENT APPLICATION
TRANSMITTAL LETTER

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is a:

☒ Continuation ☐ Division ☐ Continuation-In-Part (CIP)

of the above-identified co-pending prior application in which no patenting, abandonment, or termination of proceedings has occurred. Priority to the above-identified prior application is hereby claimed under 35 U.S.C. § 120 for this continuing application. The entire disclosure of the above-identified prior application is considered as being part of the disclosure of the accompanying continuing application and is hereby incorporated by reference therein.

Enclosed are:

- ☒ Table of Contents (2 pages).
- ☒ Specification, Claim(s), and Abstract (56 pages).
- ☒ Informal drawings (10 sheets, Figures 1-8).
- ☒ Unexecuted Declaration and Power of Attorney (4 pages).
- ☒ Information Disclosure Statement (2 pages).
- ☒ Form PTO-1449 (1 page).

The filing fee is calculated below:

	Claims as Filed	Included in Basic Fee	Extra Claims	Rate	Fee Totals
Basic Fee				\$710.00	\$710.00
Total Claims:	1	- 20	= 0	x \$18.00	= \$0.00
Independents:	1	- 3	= 0	x \$80.00	= \$0.00
If any Multiple Dependent Claim(s) present:			+ \$270.00	=	\$0.00
			SUBTOTAL:	=	\$710.00
[] Small Entity Fees Apply (subtract ½ of above):			=		\$0.00
			TOTAL FILING FEE:	=	\$710.00

- [X] A check in the amount of \$710.00 to cover the filing fee is enclosed.
- [] The required filing fees are not enclosed but will be submitted in response to the Notice to File Missing Parts of Application.
- [X] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing; the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

By

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Date March 19, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

**TREATMENT OF DIABETES MELLITUS AND
INSULIN RECEPTOR SIGNAL TRANSDUCTION**

5

TABLE OF CONTENTS

Page

	1. INTRODUCTION	1
10	2. BACKGROUND OF THE INVENTION	1
	2.1. SIGNAL TRANSDUCTION	1
	2.2. THE INSULIN RECEPTOR	4
	2.3. DIABETES MELLITUS	5
15	3. SUMMARY OF THE INVENTION	7
	4. BRIEF DESCRIPTION OF THE FIGURES	8
	5. DETAILED DESCRIPTION OF THE INVENTION	11
20	5.1. MODULATION OF PTPs THAT REGULATE IR SIG- NAL TRANSDUCTION	12
	5.1.1. 'USE OF COMPOUNDS THAT MODULATE THE IR PTP	14
	5.1.2. RPTP ANTIBODIES	14
25	5.1.3. GENE THERAPY	16
	5.1.4. ANTISENSE AND RIBOZYME APPROACHES	17
	5.1.5. PHARMACEUTICAL FORMULATIONS AND MODES OF ADMINISTRATION	19
	5.2. ASSAY SYSTEMS FOR DRUG SCREENING	23
30	5.2.1. COEXPRESSION OF RPTPS AND IR-PTK AND GENERATION OF ENGINEERED CELL LINES	25
	5.2.2. SCREENING ASSAYS	32

35

004050 03501860

Page

6.	EXAMPLE: TRANSIENT COEXPRESSION OF THE INSULIN RECEPTOR AND PTP	41
5	6.1. MATERIAL AND METHODS	41
	6.2. RESULTS	42
7.	EXAMPLE: DEMONSTRATION OF AN <i>IN VIVO</i> SELEC- TION SYSTEM FOR INSULIN RECEPTOR ACTIVATION .	44
10	7.1. MATERIALS AND METHODS	44
	7.2. SELECTION AND ANALYSIS OF CELLS BY TRANSFECTION WITH cDNAS ENCODING PTPS . .	45
	7.2.1. INSULIN-INDUCED CHANGE IN PHENOTYPE	45
15	7.2.2. AUTOPHOSPHORYLATION ASSAY BY WESTERN BLOT	46
8.	Example: Direct interaction between IR and RPTP α	47
20	8.1. Materials and Methods	47
	8.2. Coimmunoprecipitation of RPTP α with IR .	48
	8.3. Demonstration of elution of RPTP α from autophosphorylated IR	49
25	9. Example: Screening Assay for Inhibitors of Insulin Receptor-Related Phosphatase Activity	51